Detalles de la búsqueda
1.
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials.
Ann Surg Oncol
; 26(12): 3892-3901, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31350646
2.
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
Lancet Oncol
; 17(3): 345-356, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26869049
3.
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.
Int J Cancer
; 137(12): 2981-8, 2015 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26100253
4.
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
Breast Cancer Res Treat
; 152(2): 377-87, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26109347
5.
Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials.
Breast Cancer Res Treat
; 150(1): 127-39, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25677740
6.
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Lancet Oncol
; 15(7): 747-56, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24794243
7.
Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma.
Breast Cancer Res Treat
; 144(1): 153-62, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24504379
8.
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Lancet Oncol
; 13(2): 135-44, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22257523
9.
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.
Breast Cancer Res Treat
; 125(1): 145-56, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21042932
10.
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
Breast Cancer Res Treat
; 123(2): 437-45, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20623180
11.
Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer--a prospective multicenter phase II trial (PRIMOVAR).
Oncol Rep
; 22(3): 605-13, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19639211
12.
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
Breast Cancer Res
; 10(2): R30, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18380893
13.
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
J Clin Oncol
; 36(22): 2281-2287, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29791287
14.
Clinical response by palpation during primary systemic therapy with four dose-dense cycles doxorubicin and docetaxel in patients with operable breast cancer: further results from a randomised controlled trial.
Eur J Cancer
; 43(11): 1654-61, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17544652
15.
Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial.
Clin Cancer Res
; 23(18): 5384-5393, 2017 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28679772
16.
Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Eur J Cancer
; 84: 1-8, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28768217
17.
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
J Clin Oncol
; 23(12): 2676-85, 2005 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-15837982
18.
Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy.
Eur J Cancer
; 53: 65-74, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26693900
19.
Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
Clin Cancer Res
; 21(13): 2924-31, 2015 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25825476
20.
Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis.
Clin Breast Cancer
; 3(4): 276-80, 2002 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-12425756